MedPath

DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5%

DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5%

Approved
Approval ID

888b2203-469f-d599-e053-2995a90a7de1

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 10, 2019

Manufacturers
FDA

Sincerus Florida, LLC

DUNS: 080105003

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5%

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code72934-1061
Product Classification
G
Generic Name
DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5%
Product Specifications
Route of AdministrationTOPICAL
Effective DateMay 10, 2019
FDA Product Classification

INGREDIENTS (3)

DAPSONEActive
Quantity: 6 g in 100 g
Code: 8W5C518302
Classification: ACTIB
SPIRONOLACTONEActive
Quantity: 5 g in 100 g
Code: 27O7W4T232
Classification: ACTIB
NIACINAMIDEActive
Quantity: 2 g in 100 g
Code: 25X51I8RD4
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5% - FDA Drug Approval Details